Nuvilex (PMCB) Competitors

$0.73 -0.03 (-3.55%)

Closing price 03:59 PM Eastern

Extended Trading

$0.73 -0.01 (-0.95%)

As of 05:31 PM Eastern

PMCB vs. SKYE, SNTI, DARE, PLRZ, and LSTA

Should you be buying Nuvilex stock or one of its competitors? The main competitors of Nuvilex include Skye Bioscience (SKYE), Senti Biosciences (SNTI), Dare Bioscience (DARE), Polyrizon (PLRZ), and Lisata Therapeutics (LSTA). These companies are all part of the "pharmaceutical products" industry.

How does Nuvilex compare to Skye Bioscience?

Nuvilex (NASDAQ:PMCB) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, media sentiment, institutional ownership, dividends, valuation and risk.

: 34.2% of Nuvilex shares are owned by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are owned by institutional investors. 11.0% of Nuvilex shares are owned by insiders. Comparatively, 3.0% of Skye Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
: Nuvilex has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500. Comparatively, Skye Bioscience has a beta of 3.03, indicating that its stock price is 203% more volatile than the S&P 500.
: Skye Bioscience has a consensus target price of $9.80, indicating a potential upside of 1,017.19%. Given Skye Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Skye Bioscience is more favorable than Nuvilex.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nuvilex
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Skye Bioscience
1 Sell rating(s)

2 Hold rating(s)

4 Buy rating(s)

1 Strong Buy rating(s)
2.63
: Nuvilex's return on equity of 2.13% beat Skye Bioscience's return on equity.
Company Net Margins Return on Equity Return on Assets
Nuvilex N/A 2.13% 1.69%
Skye Bioscience N/A -143.59% -119.89%
: In the previous week, Skye Bioscience had 1 more articles in the media than Nuvilex. MarketBeat recorded 1 mentions for Skye Bioscience and 0 mentions for Nuvilex. Nuvilex's average media sentiment score of 0.00 equaled Skye Bioscience'saverage media sentiment score.
Company Overall Sentiment
Nuvilex Neutral
Skye Bioscience Neutral
: Nuvilex is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Nuvilex N/A N/A $30.66M -$1.12 N/A
Skye Bioscience N/A N/A -$55.92M -$1.40 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.63

Company	Net Margins	Return on Equity	Return on Assets
Nuvilex	N/A	2.13%	1.69%
Skye Bioscience	N/A	-143.59%	-119.89%

Company	Overall Sentiment
Nuvilex	Neutral
Skye Bioscience	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvilex	N/A	N/A	$30.66M	-$1.12	N/A
Skye Bioscience	N/A	N/A	-$55.92M	-$1.40	N/A

Summary

Skye Bioscience beats Nuvilex on 7 of the 13 factors compared between the two stocks.

How does Nuvilex compare to Senti Biosciences?

Senti Biosciences (NASDAQ:SNTI) and Nuvilex (NASDAQ:PMCB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

: 25.7% of Senti Biosciences shares are held by institutional investors. Comparatively, 34.2% of Nuvilex shares are held by institutional investors. 3.1% of Senti Biosciences shares are held by insiders. Comparatively, 11.0% of Nuvilex shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
: Senti Biosciences has a beta of 2.09, indicating that its stock price is 109% more volatile than the S&P 500. Comparatively, Nuvilex has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500.
: Senti Biosciences presently has a consensus target price of $8.50, indicating a potential upside of 790.99%. Given Senti Biosciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Senti Biosciences is more favorable than Nuvilex.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Senti Biosciences
1 Sell rating(s)
0 Hold rating(s)

3 Buy rating(s)

1 Strong Buy rating(s)
2.80
Nuvilex
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: Nuvilex's return on equity of 2.13% beat Senti Biosciences' return on equity.
Company Net Margins Return on Equity Return on Assets
Senti Biosciences N/A -301.48% -90.03%
Nuvilex N/A 2.13% 1.69%
: In the previous week, Senti Biosciences had 1 more articles in the media than Nuvilex. MarketBeat recorded 1 mentions for Senti Biosciences and 0 mentions for Nuvilex. Senti Biosciences' average media sentiment score of 0.00 equaled Nuvilex'saverage media sentiment score.
Company Overall Sentiment
Senti Biosciences Neutral
Nuvilex Neutral
: Nuvilex has lower revenue, but higher earnings than Senti Biosciences. Nuvilex is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Senti Biosciences $20K 1,485.38 -$61.44M -$3.19 N/A
Nuvilex N/A N/A $30.66M -$1.12 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-301.48%	-90.03%
Nuvilex	N/A	2.13%	1.69%

Company	Overall Sentiment
Senti Biosciences	Neutral
Nuvilex	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$20K	1,485.38	-$61.44M	-$3.19	N/A
Nuvilex	N/A	N/A	$30.66M	-$1.12	N/A

Summary

Senti Biosciences beats Nuvilex on 8 of the 14 factors compared between the two stocks.

How does Nuvilex compare to Dare Bioscience?

Dare Bioscience (NASDAQ:DARE) and Nuvilex (NASDAQ:PMCB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

: 6.7% of Dare Bioscience shares are held by institutional investors. Comparatively, 34.2% of Nuvilex shares are held by institutional investors. 4.8% of Dare Bioscience shares are held by insiders. Comparatively, 11.0% of Nuvilex shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
: Dare Bioscience has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, Nuvilex has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500.
: Dare Bioscience presently has a consensus target price of $10.00, indicating a potential upside of 205.81%. Given Dare Bioscience's stronger consensus rating and higher probable upside, equities research analysts clearly believe Dare Bioscience is more favorable than Nuvilex.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dare Bioscience
1 Sell rating(s)
0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.33
Nuvilex
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: Nuvilex's return on equity of 2.13% beat Dare Bioscience's return on equity.
Company Net Margins Return on Equity Return on Assets
Dare Bioscience N/A N/A -56.52%
Nuvilex N/A 2.13% 1.69%
: In the previous week, Dare Bioscience's average media sentiment score of 0.00 equaled Nuvilex'saverage media sentiment score.
Company Overall Sentiment
Dare Bioscience Neutral
Nuvilex Neutral
: Nuvilex has lower revenue, but higher earnings than Dare Bioscience. Dare Bioscience is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Dare Bioscience $1.03M 46.22 -$13.40M -$1.25 N/A
Nuvilex N/A N/A $30.66M -$1.12 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	N/A	N/A	-56.52%
Nuvilex	N/A	2.13%	1.69%

Company	Overall Sentiment
Dare Bioscience	Neutral
Nuvilex	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.03M	46.22	-$13.40M	-$1.25	N/A
Nuvilex	N/A	N/A	$30.66M	-$1.12	N/A

Summary

Nuvilex beats Dare Bioscience on 7 of the 12 factors compared between the two stocks.

How does Nuvilex compare to Polyrizon?

Polyrizon (NASDAQ:PLRZ) and Nuvilex (NASDAQ:PMCB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Polyrizon N/A N/A -$3.34M N/A N/A
Nuvilex N/A N/A $30.66M -$1.12 N/A
: Polyrizon has a beta of -2.04, indicating that its share price is 304% less volatile than the S&P 500. Comparatively, Nuvilex has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500.
: 34.2% of Nuvilex shares are owned by institutional investors. 11.0% of Nuvilex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
: In the previous week, Polyrizon had 4 more articles in the media than Nuvilex. MarketBeat recorded 4 mentions for Polyrizon and 0 mentions for Nuvilex. Polyrizon's average media sentiment score of 0.18 beat Nuvilex's score of 0.00 indicating that Polyrizon is being referred to more favorably in the media.
Company Overall Sentiment
Polyrizon Neutral
Nuvilex Neutral
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Polyrizon
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Nuvilex
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: Nuvilex's return on equity of 2.13% beat Polyrizon's return on equity.
Company Net Margins Return on Equity Return on Assets
Polyrizon N/A N/A N/A
Nuvilex N/A 2.13% 1.69%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A
Nuvilex	N/A	N/A	$30.66M	-$1.12	N/A

Company	Overall Sentiment
Polyrizon	Neutral
Nuvilex	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Polyrizon	N/A	N/A	N/A
Nuvilex	N/A	2.13%	1.69%

Summary

Nuvilex beats Polyrizon on 6 of the 8 factors compared between the two stocks.

How does Nuvilex compare to Lisata Therapeutics?

Lisata Therapeutics (NASDAQ:LSTA) and Nuvilex (NASDAQ:PMCB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation.

: Nuvilex has lower revenue, but higher earnings than Lisata Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Lisata Therapeutics $170K 175.23 -$16.59M -$1.91 N/A
Nuvilex N/A N/A $30.66M -$1.12 N/A
: Lisata Therapeutics has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. Comparatively, Nuvilex has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500.
: 8.9% of Lisata Therapeutics shares are owned by institutional investors. Comparatively, 34.2% of Nuvilex shares are owned by institutional investors. 9.1% of Lisata Therapeutics shares are owned by company insiders. Comparatively, 11.0% of Nuvilex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
: In the previous week, Lisata Therapeutics had 1 more articles in the media than Nuvilex. MarketBeat recorded 1 mentions for Lisata Therapeutics and 0 mentions for Nuvilex. Lisata Therapeutics' average media sentiment score of 0.00 equaled Nuvilex'saverage media sentiment score.
Company Overall Sentiment
Lisata Therapeutics Neutral
Nuvilex Neutral
: Lisata Therapeutics presently has a consensus target price of $15.00, indicating a potential upside of 358.72%. Given Lisata Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Lisata Therapeutics is more favorable than Nuvilex.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lisata Therapeutics
1 Sell rating(s)
1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
Nuvilex
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: Nuvilex's return on equity of 2.13% beat Lisata Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Lisata Therapeutics N/A -85.50% -70.85%
Nuvilex N/A 2.13% 1.69%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lisata Therapeutics	$170K	175.23	-$16.59M	-$1.91	N/A
Nuvilex	N/A	N/A	$30.66M	-$1.12	N/A

Company	Overall Sentiment
Lisata Therapeutics	Neutral
Nuvilex	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-85.50%	-70.85%
Nuvilex	N/A	2.13%	1.69%

Summary

Nuvilex beats Lisata Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Nuvilex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PMCB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PMCB vs. The Competition

Export

Metric	Nuvilex	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.87M	$3.10B	$6.25B	$11.87B
Dividend Yield	N/A	1.91%	2.73%	5.21%
P/E Ratio	-0.65	18.37	29.04	28.47
Price / Sales	N/A	281.30	476.61	60.92
Price / Cash	N/A	50.43	27.62	36.52
Price / Book	0.10	4.33	9.67	6.67
Net Income	$30.66M	$72.19M	$3.55B	$332.53M
7 Day Performance	-3.55%	2.03%	1.70%	2.01%
1 Month Performance	6.23%	6.42%	5.62%	9.19%
1 Year Performance	-38.92%	37.73%	34.41%	39.59%

Nuvilex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PMCB Nuvilex	0.7199 of 5 stars	$0.73 -3.6%	N/A	N/A	$7.87M	N/A	N/A	4
SKYE Skye Bioscience	1.7629 of 5 stars	$0.88 -1.7%	$9.80 +1,015.2%	N/A	$31.41M	N/A	N/A	11	Gap Up
SNTI Senti Biosciences	2.5988 of 5 stars	$0.92 -6.0%	$8.50 +819.0%	N/A	$30.64M	$22K	N/A	4
DARE Dare Bioscience	2.0579 of 5 stars	$2.28 +8.6%	$10.00 +338.6%	N/A	$30.58M	$1.03M	N/A	30	Upcoming Earnings Gap Up
PLRZ Polyrizon	0.316 of 5 stars	$15.90 +1.1%	N/A	N/A	$29.42M	N/A	N/A	N/A	News Coverage Analyst Upgrade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PMCB) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuvilex (PMCB) Competitors

PMCB vs. SKYE, SNTI, DARE, PLRZ, and LSTA

How does Nuvilex compare to Skye Bioscience?

Summary

How does Nuvilex compare to Senti Biosciences?

Summary

How does Nuvilex compare to Dare Bioscience?

Summary

How does Nuvilex compare to Polyrizon?

Summary

How does Nuvilex compare to Lisata Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMCB vs. The Competition

Nuvilex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuvilex (PMCB) Competitors

PMCB vs. SKYE, SNTI, DARE, PLRZ, and LSTA

How does Nuvilex compare to Skye Bioscience?

Summary

How does Nuvilex compare to Senti Biosciences?

Summary

How does Nuvilex compare to Dare Bioscience?

Summary

How does Nuvilex compare to Polyrizon?

Summary

How does Nuvilex compare to Lisata Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMCB vs. The Competition

Nuvilex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools